Skip to main content
. Author manuscript; available in PMC: 2016 Nov 28.
Published in final edited form as: N Engl J Med. 2012 Oct 1;367(19):1783–1791. doi: 10.1056/NEJMoa1209124

Figure 2. Second Interim Analysis of Overall Survival.

Figure 2

Shown are Kaplan–Meier estimates of overall survival in the intention-to-treat population, stratified according to world region, number of prior chemotherapy regimens (0 or 1 vs. >1), and site of disease involvement (visceral vs. nonvisceral). The second interim analysis was conducted on the basis of 331 deaths and met the predefined O'Brien–Fleming stopping boundary. The data-cutoff date was July 31, 2012. Median follow-up was 18.6 months (range, 0 to 41) in the lapatinib–capecitabine group and 19.1 months (range, 0 to 40) in the T-DM1 group.